MaxCyte
Stock Forecast, Prediction & Price Target
MaxCyte Financial Estimates
MaxCyte Revenue Estimates
MaxCyte EBITDA Estimates
MaxCyte Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $33.89M N/A | $44.26M 30.58% | $41.28M -6.71% | Avg: $47.26M Low: $43.29M High: $51.22M avg. 14.46% | Avg: $66.21M Low: $62.31M High: $69.95M avg. 40.09% | ||
Net Income
% change YoY
| $-20.12M N/A | $-19.78M 1.71% | $-37.92M -91.71% | Avg: $-43.04M Low: $-50.52M High: $-34.61M avg. -13.49% | Avg: $-32.29M Low: $-34.67M High: $-29.82M avg. 24.96% | ||
EBITDA
% change YoY
| $-16.61M N/A | $-20.74M -24.87% | $-44.12M -112.70% | Avg: $-27.17M Low: $-29.45M High: $-24.89M avg. 38.41% | Avg: $-38.07M Low: $-40.23M High: $-35.83M avg. -40.09% | ||
EPS
% change YoY
| -$0.22 N/A | -$0.19 13.63% | -$0.37 -94.73% | Avg: -$0.42 Low: -$0.49 High: -$0.34 avg. -12.64% | Avg: -$0.31 Low: -$0.34 High: -$0.29 avg. 24.96% | ||
Operating Expenses
% change YoY
| $48.43M N/A | $66.52M 37.34% | $84.84M 27.54% | Avg: $43.50M Low: $39.85M High: $47.15M avg. -48.72% | Avg: $60.94M Low: $57.36M High: $64.39M avg. 40.09% | ||
FAQ
What is MaxCyte stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 5.73% in 2025-2026.
We have gathered data from 5 analysts. Their low estimate is -50.52M, average is -43.04M and high is -34.61M.
What is MaxCyte stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 27.28% in 2025-2026.
We have gathered data from 4 analysts. Their low revenue estimate is $43.29M, average is $47.26M and high is $51.22M.
What is MaxCyte stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 6.16% in 2025-2026.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.49, average is -$0.42 and high is $-0.33.
What is the best performing analyst?
In the last twelve months analysts have been covering MaxCyte stock. The most successful analyst is Mark Massaro.